Alchemia Limited

The University of Queensland

Vast Bioscience Pty Limited

Johannes Zuegg

Wim F Meutermans

Gerald B Tometzki

Matthew Cooper

Robert John Capon

Avril Alexis Barbara Robertson

Frank Roger Fontaine

Mathias Francois

Jeroen Overman

Sreeman Kumar Mamidyala

Angela Aguslyarti Salim

Giovanni Abbenante

Craig Muldoon

Giang Thanh Le

Glang Le Thanh

Judy Halliday

Declan McKeveney

Rajaratnam Premraj

Wim Meutermans

Disclosed are compounds of a formula provided herein that show efficacy in the inhibition of SOX18 protein activity, and in particular with respect to the ability of SOX18 to bind DNA and/or particular protein partners. Further, methods of treating angiogenesis- and/or lymphangiogenesis-related diseases, disorders or conditions, such as cancer metastasis and vascular cancers, are provided herein.

Compounds and use thereof in methods of treatment

Inhibitors of SOX18 protein activity for treating angiogenesis-and/or lymphangiogenesis-related diseases

The invention provides a method of identifying biologically active compounds comprising: (a) designing a first library of compounds of formula (1) to scan molecular diversity wherein each compound of the library has at least two pharmacophoric groups R1 to R5 as defined below and wherein compound of the library has same number of pharmacophoric groups; (b) assaying the first library of compounds in one or more biological assay(s); and (c) designing a second library wherein each compound of the second library contains one or more additional pharmacophoric group with respect to the first library; such that the/each component of the first and second library is a compound of formula (1).

Method of drug design

The present invention relates to a method of identifying a candidate therapeutic agent. The method comprises contacting a G-Protein Coupled Receptor (GPCR) with a compound of General Formula (I), or a pharmaceutically acceptable salt thereof determining whether the compound inhibits or effects signal transduction activity of the GPCR, wherein a compound that inhibits or effects the activity of the GPCR is a candidate therapeutic agent.

Classes of compounds that interact with GPCRs

The present invention, in one aspect, provides a method of inhibiting bacterial growth by contacting bacteria with an effective amount of at least one monosaccharide compound of formula (1) as described herein: 

Antibacterial agents

Growing community of inventors

Wynnum, Australia

Johannes Zuegg